CAR-T Meeting 2024 | Mediating the high expense of CAR T-cell therapy
In this interview, Gérard de Pouvourville, PhD, ESSEC Business School, Cergy, France, discusses how the high expense of CAR T-cell therapy can be mediated. Although initial prices associated with this therapeutic approach are high, these will decrease over time as price-volume adjustments are put into place, patent loss occurs, and more biosimilars and generics become available. Manufacturing of academic CAR T-cells also presents a method to provide patients with CAR-T products at a lower cost. This interview took place at the EBMT-EHA 6th European CAR T-cell Meeting in Valencia, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Gérard de Pouvourville is a health economist and an advisory board member for the following companies: Abbott, Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb (BMS), Boehringer Ingelheim, Janssen, MSD, Novartis, Novo Nordisk, Roche, and Sanofi. He has received research funding from Amgen, BMS, Boehringer Ingelheim, MSD, Novartis, Roche, and Sanofi. He has received honoraria for his participation on the RELIEF study advisory board.
